Daniel Reisner focuses on patent and trade secret litigation involving biotechnology, pharmaceuticals, ANDA filings, medical devices and telecommunications.

For over two decades Mr. Reisner has worked on numerous trials and has broad experience in all phases of litigation for a variety of clients including Pfizer, Novartis, GSK, Sanofi and Regeneron.  His cases have involved a multitude of therapeutics and devices including Celebrex, Viagra, Gleevec, cardiac monitoring and HCV detection.

Along with David Barr, Mr. Reisner has served as the co-editor and a principal author of Pharmaceutical and Biotech Patent Law.

Associated Items

1 item
Program or Publication